Healthcare Cost Brake macrogovernor

The Healthcare Cost Brake is one of the Accord's six macrogovernors. It operates within congressionally-set corridors and activates when healthcare cost growth exceeds canonical bounds. Activation directs AHQB to intervene through reimbursement adjustments, formulary review, capacity-payment recalibration, or other cost-discipline actions within AHQB authority.

The brake's authority is structurally limited to clawback — preventing cost overruns above the corridor — and does not extend to cutting essential-floor coverage scope. Quality non-degradation is the binding constraint: cost discipline operates through pricing and efficiency, not through coverage reduction or under-treatment. This distinction is architecturally critical and is the difference between the Accord's cost-discipline approach and historical "managed care" cost-cutting that produced quality erosion.

Healthcare cost growth has been the dominant fiscal stress on US public budgets for four decades. CMS, GAO, and CBO long-term projections show healthcare cost growth driving most of the federal long-term deficit absent intervention. Universal-coverage architectures internationally have managed cost growth through institutional discipline (NICE/G-BA/CADTH-style assessment, central rate-setting, formulary discipline) — but those mechanisms operate inside healthcare governance, not as cross-architecture macrogovernors.

The Accord's design adds a macrogovernor layer because healthcare cost growth interacts with the broader fiscal architecture (payroll tax, Debt Sunset, debt-retirement timeline). If healthcare cost growth exceeds projections, the Debt Sunset macrogovernor triggers payroll tax+top-rate adjustments to maintain debt-retirement path; the Healthcare Cost Brake operates upstream of Debt Sunset to address the source of the cost pressure. The two macrogovernors are paired — Debt Sunset is the cause-agnostic fiscal backstop, Cost Brake is the healthcare-specific upstream intervention.

The clawback-only constraint exists because cost-cutting that reduces clinical quality has historically produced political reversals and population-health damage. The architecture's commitment is that cost discipline doesn't come at quality cost; the Cost Brake is structured to reflect that commitment in its authority bounds.

Trigger conditions. The Cost Brake activates when measured healthcare cost growth exceeds the canonical corridor — specific corridor bounds pending v10.2 specification (initial expectation: cost growth corridor calibrated to GDP+1% nominal as central, with bands for activation at higher growth rates). Triggers can be cumulative (sustained growth above corridor for multiple periods) or rate-based (single-period spike above defined threshold).

Activation mechanism. When triggered, the Cost Brake directs AHQB to implement cost-discipline interventions within AHQB authority. The macrogovernor sets the magnitude of required cost reduction (e.g., "reduce projected cost growth by 1.5 percentage points over next two years"); AHQB selects the specific interventions (reimbursement adjustments, formulary review, capacity-payment recalibration, contract restructuring).

Intervention boundaries. Cost-Brake activation cannot direct AHQB to: (a) reduce essential-floor coverage scope, (b) increase patient cost-sharing on the floor, (c) implement under-treatment patterns that AHQB clinical evidence does not support, (d) reduce capacity-payment to levels that would precipitate facility closures. These boundaries preserve the architecture's quality-non-degradation commitment.

Coordination with Debt Sunset. Cost-Brake interventions are designed to reduce healthcare cost growth before Debt Sunset activation is required. If Cost-Brake interventions are insufficient — healthcare cost growth continues to drive fiscal pressure beyond Debt Sunset's tolerance — Debt Sunset's payroll tax+top-rate adjustment activates. The two macrogovernors are not redundant; they operate at different points in the cost-growth response chain.

Termination. Cost-Brake activation persists until cost growth returns to within-corridor for a defined sustained period (specific period pending v10.2). Premature termination is not at AHQB or executive-branch discretion; the macrogovernor's discipline is automatic.

The Cost Brake operates through AHQB — AHQB executes the interventions within statutory authority. The macrogovernor's authority is to direct intervention magnitude; AHQB has clinical-judgment discretion on intervention selection within the magnitude target.

Pairs with the Debt Sunset Governor (governance/debt-sunset — Debt Sunset is one of the six macrogovernors and operates as the cause-agnostic fiscal backstop). Cost Brake is upstream of Debt Sunset for healthcare cost growth specifically.

Pharmaceutical pricing (governance/pharma-pricing) is a primary Cost-Brake intervention surface — formulary review and reference-price adjustment can produce material cost reduction without coverage scope changes. Capacity-payment recalibration (architecture/payment-design) is another primary intervention surface.

The Cost Brake is a cost-discipline mechanism, not a revenue mechanism. Its operation reduces total Distributed Healthcare expenditure relative to projected baseline; the savings flow through to general-fund balance and Debt Sunset-corridor headroom.

Estimated steady-state Cost-Brake savings: 0.5-1.5% of total healthcare expenditure annually relative to baseline-projection trajectory. Total expenditure baseline includes the Year 10 ~$5.55-6.25T full-deployment estimate; Cost-Brake savings are an offset to that baseline that improves over time as monitoring matures.

The clawback-only structural constraint is the architecture's quality-safety commitment. Cost-Brake interventions cannot degrade essential-floor coverage scope, increase patient cost-sharing on the floor, or implement under-treatment patterns. AHQB monitors quality outcomes during Cost-Brake activation periods with enhanced sensitivity — if cost-discipline interventions produce quality degradation, AHQB has authority to substitute alternative interventions that preserve quality.

The architecture's commitment is that cost discipline operates through provider efficiency and pharmaceutical/device pricing, not through patient-facing coverage reduction. This commitment is operationally testable: under Cost-Brake activation, quality metrics should be stable or improving, not degrading.

Cost-Brake activation is invisible to most patients in normal operation. Reimbursement adjustments, formulary review, and capacity-payment recalibration are administrative changes that don't visibly affect patient access or experience.

Visible to patients: occasionally, a specific high-cost branded medication may move to a higher-tier formulary position with a biosimilar or generic alternative recommended; this is a Cost-Brake intervention surface. Coverage of the medication-class is preserved; specific brand selection may change.

What's not visible: reduced cost growth that prevents future Cost-Brake escalations, preserves Debt Sunset-corridor headroom, and protects floor coverage scope from political pressure for cuts during fiscal stress.

Honesty about gaps. Distributed Healthcare has more unresolved specification than other Engines because operational complexity is higher; the items below are flagged for v10.2 specification or for outside expert review.

• Cost-corridor specification: precise corridor bounds (GDP+1%? GDP+0.5%? cumulative vs rate-based triggers) are pending v10.2.
• Coordination mechanics with Debt Sunset: precise sequence by which Cost-Brake exhaustion triggers Debt Sunset activation is pending.
• Activation transparency: whether Cost-Brake activation requires public announcement and AHQB intervention publication is pending (default expectation: yes, consistent with AHQB transparency norms).
• Termination criteria: specific 'sustained within-corridor' duration for Cost-Brake termination is pending.